Christopher Kim
Chairman and CMO, Director · Apimeds Pharmaceuticals US, Inc.
Individual
- 2025
- Oct 15, 2025
- 1
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Christopher Kim's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Mahkam Zanganeh - $51.95M in SMMT purchases and sales in the last 12 months
- Robert W. Duggan - $51.95M in SMMT purchases and sales in the last 12 months
- ORBIMED ADVISORS LLC - $51.68M in ELVN purchases and sales in the last 12 months
- Daniel Patrick O'Day - $51.19M in GILD purchases and sales in the last 12 months
- HRTG GPE, LLC - $50.00M in KARD purchases and sales in the last 12 months
- Redmile Group, LLC - $49.64M in ADCT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher Kim?
Christopher Kim is a corporate insider, tracked as Chairman and CMO, Director of Apimeds Pharmaceuticals US, Inc. (APUS). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Christopher Kim last file a Form 4?
The only primary Form 4 on record is dated 15 October 2025.